SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.51 CNY | +1.76% |
|
+2.18% | -6.12% |
| 05-14 | GRIFOLS CEO SAYS CAN CONFIRM SHANGHAI RAAS TRANSACTION WILL CLO… | RE |
| 04-29 | Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 49,882 | 45,972 | 42,737 | 53,164 | 49,601 | - | - |
| Enterprise Value (EV) 1 | 49,882 | 45,972 | 42,737 | 53,164 | 49,601 | 49,601 | 49,601 |
| P/E ratio | 35.2 x | 35.9 x | 22.6 x | 29.6 x | 23.5 x | 20.3 x | 18.1 x |
| Yield | - | - | - | 0.38% | 0.4% | 0.4% | 0.4% |
| Capitalization / Revenue | - | - | - | 6.68 x | 5.77 x | 5.21 x | 4.72 x |
| EV / Revenue | - | - | - | 6.68 x | 5.77 x | 5.21 x | 4.72 x |
| EV / EBITDA | - | - | - | 22.2 x | 18.8 x | 17 x | 15.1 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | - | 1.79 x | 1.58 x | 1.46 x | 1.35 x |
| Nbr of stocks (in thousands) | 6,740,788 | 6,740,788 | 6,740,788 | 6,645,481 | 6,604,635 | - | - |
| Reference price 2 | 7.400 | 6.820 | 6.340 | 8.000 | 7.510 | 7.510 | 7.510 |
| Announcement Date | 21-04-22 | 22-04-27 | 23-04-24 | 24-04-28 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 7,964 | 8,601 | 9,524 | 10,517 |
| EBITDA 1 | - | - | - | 2,395 | 2,644 | 2,923 | 3,283 |
| EBIT 1 | - | - | - | 2,225 | 2,728 | 3,139 | 3,617 |
| Operating Margin | - | - | - | 27.94% | 31.72% | 32.96% | 34.39% |
| Earnings before Tax (EBT) 1 | - | - | - | 2,204 | 2,714 | 3,125 | 3,603 |
| Net income 1 | 1,324 | 1,295 | 1,880 | 1,779 | 2,101 | 2,447 | 2,760 |
| Net margin | - | - | - | 22.34% | 24.43% | 25.69% | 26.25% |
| EPS 2 | 0.2100 | 0.1900 | 0.2800 | 0.2700 | 0.3200 | 0.3700 | 0.4150 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | 0.0300 | 0.0300 | 0.0300 | 0.0300 |
| Announcement Date | 21-04-22 | 22-04-27 | 23-04-24 | 24-04-28 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 2,029 | 2,056 | 2,038 | 2,257 | 2,250 | 2,451 | 2,183 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - |
| Net income | 548.6 | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | 0.0820 | - | 0.1140 | 0.0800 | 0.1000 | 0.0500 | 0.1000 | 0.0900 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 23-10-24 | 24-04-28 | 24-04-29 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | 6.06% | 6.9% | 7.24% | 7.6% |
| ROA (Net income/ Total Assets) | - | - | - | - | 6.4% | 6.6% | 6.7% |
| Assets 1 | - | - | - | - | 32,828 | 37,078 | 41,196 |
| Book Value Per Share 2 | - | - | - | 4.460 | 4.750 | 5.150 | 5.570 |
| Cash Flow per Share 2 | - | - | - | 0.3400 | -0.0400 | 0.4500 | 0.0400 |
| Capex 1 | - | - | - | 448 | 40 | 20 | 10 |
| Capex / Sales | - | - | - | 5.63% | 0.47% | 0.21% | 0.1% |
| Announcement Date | 21-04-22 | 22-04-27 | 23-04-24 | 24-04-28 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
7.51
CNY
Average target price
6
CNY
Spread / Average Target
-20.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.12% | 6.86B | |
| -1.26% | 89.46B | |
| +2.76% | 40.74B | |
| -12.32% | 33.03B | |
| +52.41% | 24.68B | |
| -17.39% | 15.12B | |
| -42.45% | 11.64B | |
| -10.48% | 11.79B | |
| +6.14% | 8.9B | |
| -7.72% | 8.22B |
- Stock Market
- Equities
- 002252 Stock
- Financials Shanghai RAAS Blood Products Co., Ltd.